Etoricoxib var forbundet med en statistisk signifikant lavere forekomst af behandlingsophør på grund af store stigninger i leverfunktionstests end diclofenac (0, 3% versus 5, 2%).
Etoricoxib was associated with a statistically significantly lower rate of withdrawals than diclofenac (0.3% versus 5.2%), due largely to elevations in liver function tests.